Type 2 Diabetes Mellitus: An Overview of Pathophysiology, Current Management, and Future Prospective

Sujit Ninayade, Shivani Kumbhar, Sainath Rathod, Nasreen Shaikh, Sonali Patil,

doi:10.5281/zenodo.17336957

Review Paper | Open Access
Volume 03 | Issue 10 | Article Id IJPS/250310148

Type 2 Diabetes Mellitus: An Overview of Pathophysiology, Current Management, and Future Prospective
Sujit Ninayade* Shivani Kumbhar Sainath Rathod Nasreen Shaikh Sonali Patil
METS Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik, 422003, Maharashtra, India.

Abstract

Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder characterized by insulin resistance and progressive ?-cell dysfunction, affecting over 500 million adults worldwide. This review synthesizes current understanding of T2DM pathophysiology, detailing molecular mechanisms of insulin signaling impairment, lipid dysregulation, and the role of chronic inflammation. Global epidemiology trends are examined, highlighting rising prevalence in low- and middle-income countries and the socioeconomic drivers of disease burden. Comprehensive management strategies are evaluated, including lifestyle interventions, dietary patterns, pharmacotherapy with established agents (metformin, sulfonylureas, insulin) and emerging classes (GLP-1 receptor agonists, SGLT2 inhibitors). Advances in personalized medicine, continuous glucose monitoring, and digital health tools are discussed. Finally, future prospects for T2DM care are explored, encompassing novel therapeutics targeting ?-cell preservation, gene-editing approaches, and gut microbiome modulation. By integrating pathophysiology, epidemiology, management, and future directions, this review provides a roadmap for optimizing T2DM prevention and treatment in the coming decade.

Keywords

Type 2 Diabetes Mellitus (T2DM), Insulin Resistance, ?-cell Dysfunction, Pharmacological Management, Lifestyle Interventions

Introduction

Type 2 diabetes mellitus (T2DM) represents one of the most significant global health challenges of the 21st century, characterized by chronic hyperglycaemia resulting from a complex interplay of insulin resistance and progressive β-cell dysfunction. According to the World Health Organization (WHO) and American Diabetes Association (ADA) diagnostic criteria, T2DM is diagnosed when haemoglobin A1C levels reach ≥6.5% (≥48 mmol/mol), fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L), or 2-hour plasma glucose ≥200 mg/dL (≥11.1 mmol/L) during an oral glucose tolerance test. Unlike Type 1 diabetes mellitus, which results from autoimmune destruction of pancreatic β-cells leading to absolute insulin deficiency, T2DM is distinguished by the body's inability to effectively use insulin combined with relative insulin insufficiency¹^,².

The pathophysiological distinction between T1DM and T2DM is fundamental to understanding diabetes as a heterogeneous group of disorders. While T1DM typically presents with rapid onset, significant weight loss, and ketosis risk due to complete insulin deficiency, T2DM generally manifests more insidiously with features including increased body mass index (≥25 kg/m²), absence of significant weight loss, minimal ketoacidosis risk, and less marked hyperglycemia at diagnosis. This differentiation has profound implications for treatment approaches, prognosis, and clinical management strategies³^,⁴.

Global Epidemiology And Rising Prevalence:

The global burden of T2DM has reached epidemic proportions, representing one of the fastest-growing public health crises worldwide. Current epidemiological data reveals that approximately 589 million adults aged 20-79 years are living with diabetes globally in 2024, representing 1 in 9 adults. The vast majority of these cases—more than 95%—are attributed to T2DM, with projections indicating this number will rise dramatically to 853 million by 2050, affecting 1 in 8 adults⁵.

The prevalence trajectory demonstrates alarming acceleration, with global diabetes prevalence in adults rising from 7% to 14% between 1990 and 2022. This represents more than a four-fold increase in total cases over three decades. The International Diabetes Federation's latest Atlas reveals that 4 in 5 adults with diabetes (81%) currently live in low- and middle-income countries (LMICs), where the rate of increase substantially exceeds that observed in high-income nations⁶.

Historical Context and Evolution of Understanding:

The recognition and understanding of diabetes mellitus spans millennia, with evolutionary insights shaping modern therapeutic approaches. The earliest descriptions of diabetes-like symptoms appear in the Ebers Papyrus around 1550 BC, where ancient Egyptians documented polyuria resembling diabetes. Ayurvedic physicians in the 5th-6th century BC first noted the sweet taste of diabetic urine, calling the condition "madhumeha" (honey urine).wikipedia+2

The term "diabetes" traces back to Demetrius of Apamea in the 1st century BC, with the Greek word meaning "siphon" or "to pass through". Thomas Willis coined the complete term "diabetes mellitus" in 1675, adding "mellitus" (meaning honey-sweet) to distinguish it from diabetes insipidus. Johann Peter Frank is credited with formally distinguishing diabetes mellitus from diabetes insipidus in 1794⁷.

The modern understanding of diabetes pathophysiology began emerging in the late 19th century. Joseph von Mering and Oskar Minkowski are credited with the formal discovery of the pancreas's role in diabetes in 1889. Their experimental pancreatectomy in dogs demonstrated the organ's crucial function in glucose homeostasis. Paul Langerhans's 1869 description of pancreatic cellular islets, later named "islets of Langerhans" by Édouard Laguesse in 1893, provided the anatomical foundation for understanding insulin production⁸.

The discovery and clinical application of insulin in 1921-1922 by Frederick Banting, John Macleod, Charles Best, and James Collip revolutionized diabetes treatment and saved countless lives. Étienne Lancereaux described the clinical differences between diabetes types in 1876, providing early recognition of disease heterogeneity. The patent for insulin was assigned to the University of Toronto in 1923 for a symbolic dollar to ensure widespread treatment accessibility.diabetes+2

Current Challenges and Unmet Needs:

Despite significant advances in understanding and treatment, T2DM continues to present formidable challenges that underscore the need for innovative approaches. The rapid urbanization and lifestyle changes associated with economic development have accelerated T2DM prevalence in emerging economies, where a 150% increase is projected by 2030. These regions face the "double burden of malnutrition," where both undernutrition and overnutrition coexist, potentially predisposing populations to diabetes through complex developmental programming mechanisms⁹.

The heterogeneous nature of T2DM pathophysiology presents ongoing therapeutic challenges. While insulin resistance and β-cell dysfunction represent core defects, the relative contribution of these mechanisms varies significantly between individuals and populations. This heterogeneity complicates treatment standardization and highlights the need for personalized therapeutic approaches based on individual pathophysiological profiles¹⁰.

Healthcare system inadequacies in diabetes prevention and early intervention represent critical gaps, particularly in LMICs. Current healthcare services are often unable to detect diabetic disease early and intervene timely, resulting in delayed diagnosis and advanced complications at presentation. The insufficient basic infrastructure to support healthy lifestyles in rapidly developing regions compounds prevention challenges¹¹.

Treatment accessibility and affordability remain significant barriers, with cost-related medication underuse affecting outcomes even in high-income countries. The cost of insulin increased 24% from 2017 to 2022, with spending on insulin tripling over the past decade from $8 billion in 2012 to $22.3 billion in 2022. These trends threaten treatment adherence and optimal glycemic control achievement diabetes.

Rationale for Comprehensive Review:

Regularly updating T2DM reviews is essential to integrate molecular insights—such as inflammatory pathways, metabolic memory, and tissue-specific insulin resistance—with new therapies that target multiple disease mechanisms simultaneously. The advent of dual GIP/GLP-1 agonists, SGLT2 inhibitors with proven cardiovascular benefits, and regenerative medicine demands evaluation of their mechanisms, efficacy, and real-world adoption. Concurrently, artificial pancreas systems, advanced glucose sensors, and nanotechnologies are reshaping care delivery but require alignment with healthcare infrastructure. Finally, precision medicine and pharmacogenomics promise individualized treatment but must be validated across diverse populations to ensure equitable outcomes¹².

Scope and Objectives:

Scope
This review comprehensively examines Type 2 diabetes mellitus (T2DM) by integrating four key dimensions:

Pathophysiology: Molecular and cellular mechanisms underpinning insulin resistance, β-cell dysfunction, lipid metabolism disturbances, and the role of chronic inflammation.
Epidemiology: Global prevalence trends, demographic shifts, socioeconomic determinants, and disparities across regions.
Current Management: Evaluation of lifestyle interventions (diet, physical activity), existing pharmacotherapies (metformin, sulfonylureas, insulin) and newer drug classes (GLP-1 receptor agonists, SGLT2 inhibitors), alongside advances in monitoring and digital health.
Future Prospects: Emerging therapeutic approaches (β-cell preservation, immunomodulation, gene editing, microbiome modulation) and innovations in personalized and precision medicine.

Objectives

To elucidate the complex interplay of metabolic and inflammatory pathways driving T2DM onset and progression.
To synthesize current global epidemiological data, highlighting at-risk populations and social determinants of health.
To critically appraise the efficacy, safety, and limitations of established and novel management strategies.
To explore cutting-edge research directions and technological innovations poised to transform prevention, treatment, and long-term outcomes in T2DM.

1.Pathophysiology Of Type 2 Diabetes Mellitus:

Type 2 diabetes mellitus (T2DM) represents a complex metabolic disorder characterized by progressive deterioration of glucose homeostasis due to the interplay of multiple pathophysiological mechanisms. The disease fundamentally stems from the inability of pancreatic β-cells to adequately compensate for insulin resistance, leading to chronic hyperglycemia and its associated complications¹⁰.

1.1 Core Pathophysiological Mechanisms:

Insulin Resistance:

Molecular mechanisms of insulin resistance:

Insulin resistance represents a state of diminished cellular responsiveness to insulin action, primarily affecting glucose uptake and metabolism. The molecular mechanisms underlying insulin resistance involve multiple interconnected pathways that disrupt normal insulin signaling cascades¹³.

The classical insulin signaling pathway begins with insulin binding to the insulin receptor, which undergoes autophosphorylation on tyrosine residues, activating its intrinsic tyrosine kinase activity. This activation leads to phosphorylation of insulin receptor substrate (IRS) proteins, particularly IRS-1 and IRS-2, which serve as docking platforms for downstream signaling molecules. The phosphorylated IRS proteins then recruit and activate phosphatidylinositol 3-kinase (PI3K), leading to the generation of phosphatidylinositol 3,4,5-trisphosphate (PIP3)¹⁴.(Figure 1)

Figure 1: A simplified model of insulin receptor-dependent signalling pathways¹⁵

(This figure illustrates the dual signaling pathways downstream of the insulin receptor, showing both the PI3K-Akt metabolic pathway (leading to GLUT4 translocation and glucose uptake) and the parallel CAP/Cbl pathway that functions independently of PI3K activation. The diagram demonstrates how insulin binding activates the insulin receptor tyrosine kinase, leading to IRS protein phosphorylation and subsequent activation of both pathways that are necessary for insulin-stimulated glucose transport.)

A critical molecular mechanism contributing to insulin resistance involves aberrant serine phosphorylation of IRS-1. Multiple serine kinases, including c-Jun N-terminal kinase (JNK), protein kinase C (PKC), and inhibitor of κB kinase β (IKKβ), phosphorylate IRS-1 on specific serine residues (Ser302, Ser307, Ser612, and Ser632), leading to impaired insulin receptor-IRS-1 interaction and subsequent degradation of IRS-1. This serine phosphorylation can be triggered by various factors including free fatty acids, inflammatory cytokines, and chronic hyperinsulinemia¹³.

The hexosamine biosynthesis pathway (HBP) provides another molecular mechanism for insulin resistance. Approximately 5% of glucose-6-phosphate is diverted through HBP to produce uridine 5'-diphosphate N-acetylglucosamine (UDP-GlcNAc), which serves as a substrate for O-GlcNAcylation of proteins. This post-translational modification affects key components of insulin signaling, including IRS-1/2, PI3K, and Akt, potentially competing with phosphorylation and thereby disrupting normal signaling cascades¹⁶.

Role in skeletal muscle, liver, and adipose tissue:

Skeletal muscle represents the primary site of insulin-mediated glucose disposal, accounting for approximately 80% of glucose uptake following insulin stimulation. In insulin-resistant skeletal muscle, multiple defects occur simultaneously, including impaired insulin receptor tyrosine kinase activity, decreased IRS-1 tyrosine phosphorylation, reduced PI3K activation, and defective GLUT4 translocation to the plasma membrane¹⁷.

The GLUT4 glucose transporter plays a central role in skeletal muscle insulin sensitivity. Under normal conditions, insulin stimulates GLUT4 translocation from intracellular storage vesicles to the plasma membrane through the PI3K/Akt pathway. In insulin resistance, this process is significantly impaired, leading to reduced glucose uptake despite adequate insulin levels¹⁸.

In adipose tissue, insulin resistance manifests as impaired suppression of lipolysis and reduced glucose uptake. Adipose tissue insulin resistance (Adipo-IR) is characterized by the inability of insulin to effectively suppress free fatty acid (FFA) release, leading to elevated circulating FFA levels. This dysfunction contributes to ectopic lipid deposition in non-adipose tissues, further exacerbating systemic insulin resistance¹⁹.

Hepatic insulin resistance primarily affects glucose metabolism, with impaired suppression of gluconeogenesis and glycogenolysis leading to excessive hepatic glucose production. The liver becomes resistant to insulin's ability to suppress glucose output, contributing significantly to fasting hyperglycemia observed in T2DM¹⁴.

Inflammatory Pathways And Cytokine Involvement

Chronic low-grade inflammation plays a pivotal role in the development and maintenance of insulin resistance. Pro-inflammatory cytokines, particularly tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), directly interfere with insulin signaling pathways²⁰.

TNF-α represents one of the most extensively studied inflammatory mediators in insulin resistance. It activates serine kinases, including JNK and IKKβ, leading to serine phosphorylation of IRS-1 and subsequent degradation of this crucial signaling protein. TNF-α also promotes lipolysis in adipocytes, increasing circulating FFA levels and further contributing to lipotoxicity²¹.

The IKKβ/NF-κB pathway serves as a central hub for inflammation-induced insulin resistance. Activation of this pathway by various inflammatory stimuli leads to increased expression of pro-inflammatory genes and direct interference with insulin signaling. Studies have shown that inhibition of IKKβ can improve insulin sensitivity, highlighting the therapeutic potential of targeting inflammatory pathways²⁰.

IL-1β contributes to insulin resistance through multiple mechanisms, including reduction of IRS-1 expression at both transcriptional and post-transcriptional levels. This cytokine activates extracellular signal-regulated kinase (ERK)-dependent pathways that impair insulin signaling. IL-6 induces expression of suppressor of cytokine signaling (SOCS) proteins, which promote ubiquitin-mediated degradation of IRS proteins²⁰.

Free Fatty Acid Metabolism And Lipotoxicity

Elevated circulating free fatty acids represent a critical link between obesity, inflammation, and insulin resistance. The concept of lipotoxicity describes the deleterious effects of excessive lipid accumulation on cellular function and survival²².

Free fatty acids impair insulin signaling through multiple mechanisms. They activate protein kinase C (PKC) isoforms, particularly PKCθ, which phosphorylate IRS-1 on serine residues, leading to impaired insulin signaling. Additionally, FFAs promote the accumulation of bioactive lipid metabolites, including diacylglycerol (DAG) and ceramides, which further interfere with insulin action²².

Ceramides, generated through the sphingolipid metabolic pathway, represent particularly important mediators of lipotoxicity. They activate protein phosphatase 2A (PP2A) and atypical PKCζ, leading to dephosphorylation and inactivation of Akt, a key downstream effector of insulin signaling. The molecular mechanisms by which ceramides induce insulin resistance continue to be investigated, with evidence suggesting involvement of multiple pathways¹⁶.

Intramyocellular lipid (IMCL) accumulation reflects the imbalance between fatty acid supply and oxidative capacity in skeletal muscle. When fatty acid influx exceeds the muscle's capacity for β-oxidation, excess lipids are stored as triglycerides and bioactive intermediates, leading to insulin resistance. This accumulation is associated with mitochondrial dysfunction, which further impairs fatty acid oxidation and perpetuates the cycle of lipid accumulation¹⁴.

1.2 Tissue-Specific Pathophysiology

1.2.1 Skeletal Muscle

Insulin signaling pathway defects

Skeletal muscle insulin resistance involves multiple defects in the insulin signaling cascade, beginning at the level of the insulin receptor and extending through downstream effector pathways. The classical insulin signaling pathway in skeletal muscle involves insulin binding to the insulin receptor, leading to receptor autophosphorylation and activation of its intrinsic tyrosine kinase activity²³.

Following insulin receptor activation, IRS proteins, particularly IRS-1 and IRS-2, are phosphorylated on specific tyrosine residues, creating docking sites for downstream signaling molecules. The most critical downstream effector is PI3K, which generates PIP3 and activates the serine/threonine kinase Akt (also known as protein kinase B)²³.

Akt activation leads to multiple metabolic effects, including phosphorylation and inactivation of glycogen synthase kinase-3β (GSK-3β), thereby promoting glycogen synthesis. Additionally, Akt phosphorylates AS160 (Akt substrate of 160 kDa) and TBC1D1, Rab GTPase-activating proteins that regulate GLUT4 translocation to the plasma membrane²³.

In insulin-resistant skeletal muscle, multiple defects occur simultaneously throughout this signaling cascade. These include reduced insulin receptor tyrosine kinase activity, decreased IRS-1 tyrosine phosphorylation, impaired PI3K activation, reduced Akt phosphorylation, and defective GLUT4 translocation. The relative contribution of each defect may vary among individuals and with disease progression²⁴.

The mechanistic basis for these signaling defects involves both genetic and environmental factors. Mutations in genes encoding insulin receptor, IRS proteins, or PI3K can directly impair insulin signaling. However, environmental factors, particularly elevated free fatty acids and inflammatory cytokines, represent more common causes of acquired insulin resistance through their effects on insulin signaling proteins¹⁰.

1.2.2 Hepatic Insulin Resistance

Increased gluconeogenesis and glycogenolysis

Hepatic insulin resistance represents one of the most significant contributors to hyperglycemia in T2DM, characterized by the liver's inability to appropriately suppress glucose production in response to insulin. Under normal physiological conditions, insulin inhibits hepatic glucose production (HGP) through suppression of both gluconeogenesis and glycogenolysis, while promoting glucose uptake and storage as glycogen²⁵.

Gluconeogenesis dysregulation

Abnormally increased hepatic gluconeogenesis represents a primary mechanism underlying fasting hyperglycemia in T2DM patients. Studies using isotopic techniques have consistently demonstrated that increased glucose production in T2DM is predominantly attributable to enhanced gluconeogenesis rather than glycogenolysis. The rate of gluconeogenesis in T2DM patients can be elevated by 30-50% compared to healthy individuals, accounting for the majority of excess hepatic glucose output²⁶.

Multiple factors contribute to enhanced gluconeogenesis in hepatic insulin resistance. Hepatic resistance to insulin action leads to inappropriate activation of gluconeogenic pathways that are normally suppressed during fed states. Key gluconeogenic enzymes, including phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), and fructose-1,6-bisphosphatase, remain inappropriately active despite elevated insulin levels²⁷. (Figure 2)

The transcriptional regulation of gluconeogenesis involves several key transcription factors and coactivators. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) serves as a master regulator of gluconeogenic gene expression, promoting transcription of PEPCK and G6Pase. In hepatic insulin resistance, PGC-1α activity remains elevated due to impaired insulin signaling, leading to sustained gluconeogenesis²⁵.

Forkhead box protein O1 (FoxO1) represents another critical transcriptional regulator of gluconeogenesis. Under normal conditions, insulin-mediated Akt activation phosphorylates FoxO1, leading to its nuclear exclusion and inactivation. In hepatic insulin resistance, impaired Akt signaling allows FoxO1 to remain active in the nucleus, where it promotes expression of gluconeogenic genes²⁸.

Figure 2: Key Enzymes of Hepatic Gluconeogenesis²⁹

Glycogenolysis abnormalities

Hepatic glycogenolysis contributes significantly to glucose production, particularly during fasting states and early postprandial periods. In T2DM, defects in both the suppression of glycogenolysis and the regulation of glycogen synthesis contribute to hepatic insulin resistance²⁸.

Glycogen phosphorylase (GP), the rate-limiting enzyme for glycogenolysis, is normally inactivated by insulin through dephosphorylation. In hepatic insulin resistance, impaired insulin signaling leads to persistent GP activation, resulting in continued glycogen breakdown even in the presence of elevated glucose and insulin levels. Conversely, glycogen synthase (GS) activity is reduced due to impaired insulin signaling, leading to decreased glycogen storage capacity²⁸.

The regulation of hepatic glycogen metabolism involves complex interactions between hormonal signals and enzymatic cascades. Glucagon, which is often elevated in T2DM, activates protein kinase A (PKA), leading to phosphorylation and activation of GP while simultaneously phosphorylating and inactivating GS. The loss of normal insulin-glucagon balance in T2DM exacerbates these glycogenolytic defects³⁰.

Mechanisms of lipid-induced hepatic insulin resistance

The accumulation of intrahepatic lipids, particularly diacylglycerol (DAG), represents the primary mechanism linking NAFLD to hepatic insulin resistance. DAG activates protein kinase C epsilon (PKCε), which phosphorylates insulin receptor substrate-2 (IRS-2) on serine residues, leading to impaired insulin signaling specifically in hepatocytes³¹.

Studies in humans have demonstrated that hepatic DAG content is the strongest predictor of insulin resistance, accounting for approximately 64% of the variability in insulin sensitivity. The correlation between hepatic DAG and insulin resistance (r = 0.80) significantly exceeds correlations with other lipid metabolites or inflammatory markers. Importantly, DAG accumulation occurs primarily within cytoplasmic lipid droplets, and its content correlates strongly with PKCε activation³¹. (Figure 3)

Ceramides represent another class of bioactive lipids that contribute to hepatic insulin resistance, though their role appears less prominent than DAG in human studies. Ceramides can activate protein phosphatase 2A (PP2A), leading to dephosphorylation and inactivation of Akt, thereby impairing insulin signaling. The sphingolipid metabolic pathway generates ceramides from saturated fatty acids, particularly palmitate, which is commonly elevated in obesity¹⁶.

Figure 3: Molecular mechanism of diacylglycerol-PKCε-mediated hepatic insulin resistance³²

Progressive nature of NAFLD and insulin resistance

The relationship between NAFLD and insulin resistance exhibits a progressive nature, with simple steatosis potentially advancing to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. Insulin resistance severity correlates with histopathological progression, with HOMA-IR levels being significantly higher in NASH patients compared to those with simple steatosis³³.

Advanced liver fibrosis represents a particularly concerning complication, as it serves as an independent predictor of mortality in NAFLD patients. Studies have demonstrated that HOMA-IR levels are significantly elevated in patients with advanced fibrosis (stages 3-4) compared to those without significant fibrosis, even after controlling for confounding factors such as BMI, age, and gender. This relationship suggests that insulin resistance serves as an independent risk factor for fibrosis progression³³.

The mechanisms underlying fibrosis progression in insulin-resistant patients likely involve multiple pathways, including chronic inflammation, oxidative stress, and direct effects of hyperinsulinemia on hepatic stellate cells. Glucose and insulin can directly stimulate connective tissue growth factor production, promoting collagen synthesis and fibrosis development³³.

Portal vein insulin signaling

The unique anatomical position of the liver in receiving portal vein blood creates a specialized environment for insulin action that differs significantly from peripheral insulin signaling. Under physiological conditions, insulin is secreted directly into the hepatic portal vein, creating a 2-3 fold gradient between portal and systemic insulin concentrations³⁴.

Physiological importance of pulsatile insulin delivery

Physiological insulin secretion occurs in discrete pulses approximately every 5 minutes, creating oscillating insulin concentrations in the portal circulation. These pulsatile patterns are crucial for optimal hepatic insulin signaling and glucose homeostasis. Studies comparing pulsatile versus constant insulin infusion have demonstrated that pulsatile delivery is significantly more effective at suppressing hepatic glucose production²⁸.

The superiority of pulsatile insulin delivery appears to result from enhanced activation of hepatic insulin signaling pathways. Pulsatile insulin infusion leads to more robust activation of IRS-1 and IRS-2, greater Akt phosphorylation, and improved FoxO1 regulation compared to equivalent constant infusion rates. Additionally, pulsatile delivery promotes greater expression of glucokinase (GCK), a key hepatic glucose sensor that facilitates glucose uptake and storage³⁵.

Impaired pulsatility in T2DM

In T2DM, the normal pulsatile pattern of insulin secretion is significantly impaired, with reduced amplitude and altered frequency of insulin pulses. This dysregulated insulin delivery pattern contributes to hepatic insulin resistance independently of absolute insulin concentrations. When the T2DM pattern of insulin delivery is replicated experimentally, it results in impaired glucose control despite adequate insulin exposure²⁸.

The loss of pulsatile insulin delivery has multiple consequences for hepatic metabolism. Impaired pulsatility reduces the efficacy of insulin in suppressing hepatic glucose production, contributing to fasting hyperglycemia. Additionally, altered insulin pulsatility may affect hepatic lipid metabolism through impaired FoxO1 regulation, potentially contributing to the development of NAFLD³⁵.

1.2.3 Adipose Tissue Dysfunction

Adipose tissue acts as an endocrine organ, secreting adipokines that regulate glucose homeostasis, insulin sensitivity, and inflammation. In T2DM, the balance shifts toward pro-inflammatory signals, exacerbating insulin resistance.

Adiponectin, an insulin-sensitizing, anti-inflammatory adipokine, binds AdipoR1/AdipoR2 in muscle and liver to stimulate AMPK and PPARα pathways. In T2DM, adiponectin levels and receptor expression are markedly reduced—especially in obese patients—and its half-life shortens with worsening hyperglycemia, compounding insulin resistance and cardiovascular risk³⁶.
Conversely, pro-inflammatory adipokines—TNF-α, IL-6, resistin, chemerin—and emerging factors like asprosin (which promotes hepatic glucose output) rise in T2DM, correlating inversely with insulin sensitivity³⁷.
Chronic adipose inflammation features macrophage infiltration and M1 polarization driven by MCP-1 from hypertrophic adipocytes. M1 macrophages release TNF-α, IL-6, and IL-1β, activating NF-κB and JNK to serine-phosphorylate IRS proteins and impair insulin signaling in a vicious cycle³⁵.
Hypertrophic adipocytes endure hypoxia (via HIF-1α) and ER stress, further promoting inflammatory cytokine release and lipolysis. Crown-like structures—macrophages encircling dying adipocytes—highlight intense local inflammation linked to insulin resistance³⁸.
Visceral adipose tissue (VAT) poses greater metabolic risk than subcutaneous fat (SAT). VAT’s proximity to the portal vein delivers FFAs and cytokines directly to the liver. VAT adipocytes are larger, more lipolytic, and secrete higher levels of IL-6, TNF-α, and resistin, while producing less adiponectin, driving hepatic insulin resistance³⁹.
In contrast, SAT expands via hyperplasia, stores lipids safely, and maintains higher insulin sensitivity and anti-inflammatory adipokine profiles, offering metabolic protection. When SAT storage capacity is exceeded, lipids shift to VAT and ectopic sites, aggravating metabolic dysfunction⁴⁰.

1.3 Environmental and Genetic Factors

Environmental factors powerfully shape type 2 diabetes risk and progression, with diet and activity patterns among the most modifiable contributors. Nutritional quality—particularly carbohydrate type and dietary pattern—strongly influences glycemic control: low–glycemic index foods (whole grains, legumes, nonstarchy vegetables) reduce postprandial excursions and lower HbA1c by 0.2–0.5% through improved insulin sensitivity and β-cell relief. Mediterranean and plant-based diets, rich in fiber, monounsaturated fats, antioxidants, and phytochemicals, consistently reduce T2DM incidence by up to 30% and lower HbA1c 0.2–0.4% while supporting weight management and anti-inflammatory effects. Low-carbohydrate diets (<130 g/day) further decrease HbA1c by 0.1–0.5% primarily by reducing glucose load and promoting weight loss, though long-term safety and sustainability require further study. Physical inactivity and prolonged sitting independently double diabetes risk, impair GLUT4-mediated glucose uptake, reduce AMPK activation, and promote inflammation and oxidative stress, even in individuals meeting exercise guidelines. Lastly, gut microbiome dysbiosis—marked by reduced Firmicutes, increased Bacteroides, and lower SCFA production—contributes to insulin resistance through altered bile acid signaling, leaky gut–driven inflammation, and impaired incretin release, highlighting diet–microbiome interactions as targets for intervention⁴¹^,⁴².

1.3.1 Genetic Predisposition

Genome-Wide Association Studies (GWAS) in Type 2 Diabetes Mellitus

Genome-wide association studies have identified over 140 genetic variants that influence type 2 diabetes mellitus (T2DM) susceptibility, transforming our understanding of its heritable architecture. The largest meta-analysis to date uncovered 143 risk loci at genome-wide significance, including 42 novel signals, collectively explaining a modest proportion of disease heritability³⁹.

Major Susceptibility Loci

TCF7L2 remains the most strongly associated common variant (odds ratio 1.3–1.4 per risk allele). It regulates Wnt signaling critical for pancreatic β-cell proliferation and function¹⁶.
PPARG variants affect adipocyte differentiation and insulin sensitivity.
KCNJ11 encodes the Kir6.2 potassium channel subunit, modulating insulin secretion.
IGF2BP2 influences β-cell development via mRNA regulation.

Approximately 60% of identified loci impact insulin secretion, underscoring β-cell dysfunction as the primary genetic driver of T2DM, while the remainder affect insulin action and glucose metabolism pathways¹⁶.

Population-Specific Discoveries

East Asian cohorts revealed novel signals near KCNQ1, MTNR1B, and CDKN2A/B, which show stronger associations in Asian populations.
An Indian GWAS identified a unique variant at 2q21 near TMEM163, linked to reduced fasting insulin and increased insulin resistance.
Preliminary studies in African populations suggest additional, distinct risk variants.

These findings emphasize the necessity of diverse cohorts to capture the full spectrum of T2DM genetic risk and improve global applicability of genetic insights⁴³.

Functional Genomics and Regulatory Mechanisms
Integration with expression quantitative trait loci (eQTL) and epigenetic datasets has pinpointed 33 putative functional genes. Many risk variants lie in noncoding regions, influencing gene expression via DNA methylation or histone modifications. Notable examples include regulatory variants at CAMK1D, TP53INP1, and ATP5G1, which modulate transcriptional networks central to β-cell health³⁹.

Polygenic Risk Scores (PRS)
PRS aggregate the effects of multiple loci to estimate individual genetic risk. Current T2DM PRS achieve moderate discrimination (AUROC 0.60–0.67) and can stratify individuals into risk categories (odds ratios 1.9–4.4 for high vs. low genetic risk). Performance is greater in younger, leaner individuals and declines when applied across ethnically diverse cohorts, highlighting the need for population-specific PRS development³⁹.

Clinical Utility and Limitations
While PRS correlate with earlier onset, insulin resistance severity, and complication risk, their present discriminatory power limits routine clinical use. Genetic risk explains only a fraction of overall T2DM risk, with lifestyle and environmental factors remaining dominant determinants. Hence, lifestyle interventions continue to be the cornerstone of prevention and management irrespective of genetic predisposition¹³.

Gene–Environment Interactions
Emerging evidence indicates that genetic susceptibility can modify responses to physical activity and dietary interventions. Individuals with high genetic risk may derive greater benefit from exercise, while gene–diet interactions—though biologically plausible—have yet to translate into actionable clinical guidance due to inconsistent replication and limited study power⁴⁴.

Implications for Precision Medicine
GWAS have laid the groundwork for precision medicine in T2DM by identifying molecular pathways for targeted therapies and risk stratification. Future advances will depend on incorporating multi-ethnic genetic data, refining PRS, and elucidating gene–environment interplay to tailor prevention and treatment strategies more effectively⁴⁵.

2. Current Management Strategies

2.1 Lifestyle Interventions

2.1.1 Dietary Management

Evidence-based dietary approaches emphasize pattern-based nutrition therapy over rigid macronutrient prescriptions. Current guidelines prioritize Mediterranean, DASH, and plant-based diets that focus on whole foods, vegetables, fruits, whole grains, legumes, nuts, and lean proteins while limiting processed foods and refined sugars. Individualized approaches consider patient preferences, cultural factors, and metabolic goals rather than one-size-fits-all recommendations⁴⁶.

Macronutrient recommendations avoid rigid percentage targets, instead emphasizing carbohydrate quality over quantity with high-fiber, low-glycemic sources. Protein intake typically comprises 15-20% of calories from lean sources, while fat intake focuses on monounsaturated and polyunsaturated sources, limiting saturated fat to <10% of calories⁴⁷.

Mediterranean and low-carbohydrate diets show strong evidence for T2DM management. The Mediterranean pattern demonstrates improvements in HbA1c, cardiovascular outcomes, and mortality. Low-carbohydrate approaches (<130g daily) provide short-term glycemic improvement and weight loss, with very low-carbohydrate diets (<50g daily) considered for motivated individuals under medical supervision⁴⁸.

Intermittent fasting and caloric restriction represent emerging approaches, with time-restricted eating (16:8 method) showing promise for weight loss and glycemic control. However, these require careful medication timing consideration. Moderate caloric restriction (500-750 calories daily) remains fundamental for sustainable weight loss⁴⁹.

2.1.2 Physical Activity

Exercise prescription for T2DM recommends at least 150 minutes weekly of moderate-intensity aerobic activity plus two resistance training sessions targeting major muscle groups. Prescriptions should be individualized based on fitness level, comorbidities, and preferences⁵⁰.

Aerobic vs. resistance training both provide independent glucose control benefits, with combination training showing superior HbA1c reductions of 0.5-0.7%. Aerobic exercise improves insulin sensitivity and cardiovascular fitness, while resistance training enhances muscle mass and glucose uptake capacity⁵⁰.

Breaking sedentary behavior has become a specific guideline recommendation, with activity breaks every 30 minutes improving postprandial glucose control. Even light-intensity activities provide metabolic benefits when interrupting prolonged sitting⁵¹.

2.1.3 Weight Management

Weight loss targets and benefits recommend initial goals of 5-10% body weight reduction, potentially achieving 0.5-1.0% HbA1c improvement. Greater weight loss (>15%) may lead to diabetes remission in recently diagnosed patients.idf+1

Bariatric surgery considerations are recommended for BMI ≥35 kg/m² with inadequate nonsurgical weight loss and comorbidity improvement. Surgery may be considered for BMI 30-34.9 kg/m² with inadequate glycemic control despite optimal medical management⁴⁹.

Behavioral interventions incorporating goal setting, self-monitoring, and social support significantly improve outcomes. Digital health tools and group-based programs enhance accessibility and cost-effectiveness.idf+1

2.2 Pharmacological Management

2.2.1 First-Line Therapy

Metformin mechanism and efficacy involves inhibiting hepatic gluconeogenesis through AMPK activation, reducing glucose output by 20-30% without hypoglycemia risk. It typically reduces HbA1c by 1.0-1.5% with additional benefits including modest weight loss and cardiovascular protection⁵².

Contraindications and side effects include severe renal impairment (eGFR <30 mL/min/1.73m²), metabolic acidosis, and severe hepatic impairment. Gastrointestinal effects affect 20-30% of patients but are usually transient and manageable with gradual dose escalation⁵².

Combination therapy approaches are indicated when monotherapy fails to achieve HbA1c targets. Second-line selection depends on cardiovascular disease, heart failure, kidney disease, weight concerns, and hypoglycemia risk, with SGLT2 inhibitors preferred for cardiovascular/renal protection and GLP-1 agonists for weight loss⁵².

2.2.2 Second-Line and Add-On Therapies

Traditional Agents include sulfonylureas and meglitinides that stimulate insulin secretion but carry hypoglycemia and weight gain risks. Thiazolidinediones (pioglitazone) improve insulin sensitivity but may cause fluid retention and heart failure. Alpha-glucosidase inhibitors delay carbohydrate absorption with modest efficacy but significant gastrointestinal side effects. Insulin therapy remains essential for severe hyperglycemia or advanced disease⁵².

Incretin-Based Therapies include DPP-4 inhibitors providing glucose-lowering with weight neutrality and low hypoglycemia risk. GLP-1 receptor agonists offer superior weight loss and cardiovascular protection but require injection and may cause gastrointestinal side effects. Dual GIP/GLP-1 receptor agonists (tirzepatide) demonstrate superior glycemic control and weight loss compared to single incretin therapies⁵².

SGLT2 Inhibitors block renal glucose reabsorption, providing glucose-lowering independent of insulin. They demonstrate significant cardiovascular benefits including reduced heart failure hospitalizations and cardiovascular death. Renal protective effects include slowing chronic kidney disease progression. Safety considerations include increased genital infections, diabetic ketoacidosis risk, and rare necrotizing fasciitis⁵².

2.3 Individualized Treatment Approaches

2.3.1 Glycemic Targets

HbA1c goals are individualized based on age, comorbidities, life expectancy, and hypoglycemia risk. Standard targets of <7% apply to most adults, with more stringent goals (<6.5%) for younger patients without comorbidities, and less stringent goals (<8%) for older adults with multiple comorbidities. Time-in-range concepts using continuous glucose monitoring target 70-180 mg/dL for >70% of time, providing more comprehensive glycemic assessment.idf+1

2.3.2 Cardiovascular Risk Management

Blood pressure control targets <130/80 mmHg for most patients, with ACE inhibitors or ARBs preferred as first-line agents. Lipid management includes high-intensity statin therapy for most patients, with LDL goals <70 mg/dL for very high-risk individuals. Antiplatelet therapy with aspirin is recommended for secondary prevention and may be considered for primary prevention in high-risk patients without bleeding risk.idf+1

2.3.3 Complication Prevention and Management

Screening protocols include annual eye examinations, foot inspections, kidney function monitoring, and cardiovascular risk assessment. Early intervention strategies emphasize prompt treatment of risk factors and complications to prevent progression. Multidisciplinary care approaches involving endocrinologists, certified diabetes educators, dietitians, pharmacists, and mental health professionals optimize outcomes through comprehensive, coordinated care addressing medical, educational, and psychosocial needs⁴⁹.

Future Prospects and Emerging Therapies:

Recent advances in molecular biology, bioengineering, and digital health are revolutionizing the management of type 2 diabetes mellitus (T2DM), shifting focus from solely controlling blood glucose to achieving durable disease modification, restoring β-cell function, and enabling precision medicine. Emerging pharmacological strategies include novel incretin therapies such as triple hormone agonists (GLP-1, GIP, glucagon) that activate multiple pathways to enhance insulin secretion, suppress appetite, and boost energy expenditure, showing promise for up to 2% HbA1c reduction and significant weight loss in early trials. Oral GLP-1 receptor agonists like orforglipron are being developed to eliminate injections, demonstrating encouraging phase III results with HbA1c reductions of 1.0–1.3%. Long-acting formulations, including depot injections and implantable pumps, aim to sustain receptor engagement, improve adherence, and stabilize glycemic control⁵³.

Innovative drug targets are also in development. Glucagon receptor antagonists reduce hepatic glucose production and may benefit nonalcoholic fatty liver disease. Strategies like immunomodulation and bioengineered islets — including encapsulated β-like cell scaffolds — aim to protect and restore endogenous β-cell mass, potentially offering long-term remission, as early human studies indicate functional insulin secretion beyond a year⁵⁴.

Dual SGLT1/2 inhibitors such as sotagliflozin offer greater postprandial and fasting glucose reductions, with added benefits on cardiovascular and renal health, by simultaneously decreasing renal and intestinal glucose absorption. They synergize gut microbiota modulation with natriuresis, expanding metabolic control⁵⁴.

Regenerative medicine and cell therapy are progressing rapidly. β-cell regeneration approaches utilize small molecules and growth factors to reprogram pancreatic progenitors or convert α-cells into insulin producers, with promising preclinical results. Induced pluripotent stem cells (iPSCs) derived from patients can be differentiated into β-cells, encapsulated to prevent immune rejection, and have shown safety and efficacy in early trials. Islet cell transplantation is also advancing with improved isolation, viability, and microencapsulation techniques, leading to increased graft survival and reduced immunosuppressive dependence⁵⁵.

Gene editing technologies, like CRISPR-Cas9, aim to modify genes involved in immune recognition and β-cell resilience, creating universal donor cells that are safer for transplantation. In vivo and ex vivo gene therapies utilizing viral vectors are under clinical evaluation to enable long-term insulin or GLP-1 expression, offering potential for durable treatment⁵⁶.

Personalized medicine is further advancing through pharmacogenomics, where genetic profiling guides drug selection and dosing, enhancing efficacy and reducing adverse effects. Multi-omics approaches and AI-driven predictive models are enabling real-time risk stratification, treatment monitoring, and decision support. This integrated approach promises to optimize individualized interventions, ultimately transforming T2DM management from a reactive to a preemptive, precision-based paradigm⁵⁷.

Overall, the synergy of pharmacological innovation, regenerative strategies, gene editing, advanced monitoring, and personalized approaches is poised to dramatically improve outcomes, reduce complications, and move towards a potential cure for T2DM in the near future⁵⁷.

CONCLUSION:

Type 2 diabetes mellitus remains a formidable global health challenge driven by multifactorial pathophysiology and accelerated by demographic and lifestyle transitions. Advances in understanding insulin resistance, β-cell dysfunction, and inflammatory pathways have enabled more targeted interventions. Integrated management combining lifestyle optimization, established pharmacotherapies, and novel agents such as GLP-1 receptor agonists and SGLT2 inhibitors improves glycemic control and cardiovascular outcomes. Emerging technologies—including continuous glucose monitors, telemedicine platforms, and digital therapeutics—further enhance personalized care. Looking ahead, breakthroughs in β-cell preservation, immunomodulation, gene editing, and microbiome therapeutics hold promise for altering disease trajectory and achieving durable remission. Collaborative efforts spanning research, clinical practice, and public health policy are essential to translate these innovations into equitable, scalable solutions. By aligning mechanistic insights with patient-centered strategies and forward-looking research, the diabetes community can drive progress toward prevention, optimal management, and ultimately, a transformation in long-term outcomes.

REFERENCES

American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, et al. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care. 2024 Jan 1;47(Supplement_1):S20–42.
Hossain MdJ, Al?Mamun Md, Islam MdR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024 Mar;7(3):e2004.
Arneth B, Arneth R, Shams M. Metabolomics of Type 1 and Type 2 Diabetes. Int J Mol Sci. 2019 May 18;20(10):2467.
Sharma UK, Pujani M, . A. Type-II-Diabetes Mellitus- Etiology, Epidemiology, Risk Factors and Diagnosis and Insight into Demography (Urban Versus Rural). Int J Health Sci Res. 2024 Jan 19;14(1):283–90.
Diabetes around the world - 2024.
Zhou B, Rayner AW, Gregg EW, Sheffer KE, Carrillo-Larco RM, Bennett JE, et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. The Lancet. 2024 Nov;404(10467):2077–93.
Alam S, Eqbal K, Patel I, Mulla I, Ansari S, Ayesha B. The history of diabetes: From olden days to discovering insulin. Int J Unani Integr Med. 2017 July 1;1(1):25–8.
Vecchio I, Tornali C, Bragazzi NL, Martini M. The Discovery of Insulin: An Important Milestone in the History of Medicine. Front Endocrinol. 2018 Oct 23;9:613.
Shahid SM, Jawed M. Global epidemiology and burden of type 2 diabetes mellitus in children and young adults. J Public Health Emerg. 2025 Sept;9:30–30.
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275.
Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020 Sept 8;10(1):14790.
Nurkolis F, Harbuwono DS, Taslim NA, Soegondo S, Suastika K, Sparringa RA, et al. New insight on dietary strategies to increase insulin sensitivity and reduce diabetes prevalence: an expert perspective and recommendation. Discov Food. 2025 May 16;5(1):136.
Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes. 2010;1(3):68.
Abdul-Ghani MA, DeFronzo RA. Pathogenesis of Insulin Resistance in Skeletal Muscle. J Biomed Biotechnol. 2010;2010:1–19.
Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000 July 15;106(2):165–9.
Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J. 2022 Jan 31;46(1):15–37.
Shepherd PR, Kahn BB. Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus. Epstein FH, editor. N Engl J Med. 1999 July 22;341(4):248–57.
Huang S, Czech MP. The GLUT4 Glucose Transporter. Cell Metab. 2007 Apr;5(4):237–52.
Gastaldelli A, Gaggini M, DeFronzo RA. Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. Diabetes. 2017 Apr 1;66(4):815–22.
Tilg H, Moschen AR. Inflammatory Mechanisms in the Regulation of Insulin Resistance. Mol Med. 2008 Mar;14(3–4):222–31.
Chen L, Chen R, Wang H, Liang F. Mechanisms Linking Inflammation to Insulin Resistance. Int J Endocrinol. 2015;2015:1–9.
Yaz?c? D, Demir SÇ, Sezer H. Insulin Resistance, Obesity, and Lipotoxicity. In: Engin AB, Engin A, editors. Obesity and Lipotoxicity [Internet]. Cham: Springer International Publishing; 2024 [cited 2025 Oct 4]. p. 391–430. (Advances in Experimental Medicine and Biology; vol. 1460). Available from: https://link.springer.com/10.1007/978-3-031-63657-8_14
Wang L, Chang L, Ma Y, Jia Y, Gao B, Cui W, et al. Mechanomedicine for Addressing Skeletal Muscle Insulin Resistance. Endocr Rev. 2025 Sept 16;46(5):652–69.
Abdul-Ghani MA, DeFronzo RA. Pathogenesis of Insulin Resistance in Skeletal Muscle. J Biomed Biotechnol. 2010;2010:1–19.
Jiang S, Young J, Wang K, Qian Y, Cai L. Diabetic?induced alterations in hepatic glucose and lipid metabolism: The role of type 1 and type 2 diabetes mellitus (Review). Mol Med Rep. 2020 May 22;22(2):603–11.
Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992 Oct 1;90(4):1323–7.
Zhang X, Yang S, Chen J, Su Z. Unraveling the Regulation of Hepatic Gluconeogenesis. Front Endocrinol. 2019 Jan 24;9:802.
Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al. Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling. Diabetes. 2012 Sept 1;61(9):2269–79.
Zhang X, Yang S, Chen J, Su Z. Unraveling the Regulation of Hepatic Gluconeogenesis. Front Endocrinol. 2019 Jan 24;9:802.
Han HS, Kang G, Kim JS, Choi BH, Koo SH. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med. 2016 Mar 11;48(3):e218–e218.
Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci. 2011 Sept 27;108(39):16381–5.
Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014 June;510(7503):84–91.
Guven Cetin E. The Relationship between Insulin Resistance and Liver Damage in non-alcoholic Fatty Liver Patients. SiSli Etfal Hastan Tip Bul Med Bull Sisli Hosp. 2020;411–5.
Ishida T, Chap Z, Chou J, Lewis RM, Hartley CJ, Entman ML, et al. Effects of Portal and Peripheral Venous Insulin Infusion on Glucose Production and Utilization in Depancreatized, Conscious Dogs. Diabetes. 1984 Oct 1;33(10):984–90.
Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al. Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling. Diabetes. 2012 Sept 1;61(9):2269–79.
Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al. Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling. Diabetes. 2012 Sept 1;61(9):2269–79.
Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al. Pulsatile Portal Vein Insulin Delivery Enhances Hepatic Insulin Action and Signaling. Diabetes. 2012 Sept 1;61(9):2269–79.
Son J. Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes. Mol Med. 2023;
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275.
Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275.
Martín-Peláez S, Fito M, Castaner O. Mediterranean Diet Effects on Type 2 Diabetes Prevention, Disease Progression, and Related Mechanisms. A Review. Nutrients. 2020 July 27;12(8):2236.
Uusitupa M, Khan TA, Viguiliouk E, Kahleova H, Rivellese AA, Hermansen K, et al. Prevention of Type 2 Diabetes by Lifestyle Changes: A Systematic Review and Meta-Analysis. Nutrients. 2019 Nov 1;11(11):2611.
Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J. 2022 Jan 31;46(1):15–37.
Son J, Accili D. Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes. Exp Mol Med. 2023 Aug 1;55(8):1652–8.
Cruz LA, Cooke Bailey JN, Crawford DC. Importance of Diversity in Precision Medicine: Generalizability of Genetic Associations Across Ancestry Groups Toward Better Identification of Disease Susceptibility Variants. Annu Rev Biomed Data Sci. 2023 Aug 10;6(1):339–56.
American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, et al. Summary of Revisions: Standards of Care in Diabetes—2025. Diabetes Care. 2025 Jan 1;48(Supplement_1):S6–13.
Whiteley C, Benton F, Matwiejczyk L, Luscombe-Marsh N. Determining Dietary Patterns to Recommend for Type 2 Diabetes: An Umbrella Review. Nutrients. 2023 Feb 8;15(4):861.
Currenti W, Losavio F, Quiete S, Alanazi AM, Messina G, Polito R, et al. Comparative Evaluation of a Low-Carbohydrate Diet and a Mediterranean Diet in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A 16-Week Intervention Study. Nutrients. 2023 Dec 27;16(1):95.
American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, et al. Summary of Revisions: Standards of Care in Diabetes—2025. Diabetes Care. 2025 Jan 1;48(Supplement_1):S6–13.
Yuan S, Li X, Liu Q, Wang Z, Jiang X, Burgess S, et al. Physical Activity, Sedentary Behavior, and Type 2 Diabetes: Mendelian Randomization Analysis. J Endocr Soc. 2023 July 3;7(8):bvad090.
Hamilton MT, Hamilton DG, Zderic TW. Sedentary Behavior as a Mediator of Type 2 Diabetes. In: Goedecke JH, Ojuka EO, editors. Medicine and Sport Science [Internet]. S. Karger AG; 2014 [cited 2025 Oct 4]. p. 11–26. Available from: https://karger.com/chapter/doi/10.1159/000357332
American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG, Aleppo G, Bajaj M, Balapattabi K, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care. 2025 Jan 1;48(Supplement_1):S181–206.
Almeida-Oliveira A, Bonamino MH, Simões M, Villaça Martins VH, Borges Freire DP, Danowski A, et al. Landscape of Ex vivo Gene Therapies: Technological Trends and Future Prospects. Mol Ther Methods Clin Dev. 2025 Aug;101580.
Dutta D, Kamrul?Hasan ABM, Surana V, Singla R, Khandelwal D, Aggarwal S, et al. Efficacy and safety of the glucagon receptor antagonist volagidemab in type?1 diabetes: A systematic review and meta?analysis. Ann N Y Acad Sci. 2025 Jan;1543(1):94–101.
Wang KL, Tao M, Wei TJ, Wei R. Pancreatic β cell regeneration induced by clinical and preclinical agents. World J Stem Cells. 2021 Jan 26;13(1):64–77.
Ansori ANm, Antonius Y, Susilo RJk, Hayaza S, Kharisma VD, Parikesit AA, et al. Application of CRISPR-Cas9 genome editing technology in various fields: A review. Narra J. 2023 Aug 31;3(2):e184.
Almurashi AM, Rodriguez E, Garg SK. Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases. J Indian Inst Sci. 2023 Jan;103(1):205–30.